# An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

> **NCT03467958** · PHASE3 · TERMINATED · sponsor: **Celgene** · enrollment: 854 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Ozanimod

## Key facts

- **NCT ID:** NCT03467958
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-24
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 854 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03467958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03467958, "An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03467958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*